(no IDC) advancing an experimental antineuroinflammatory drug toward a phase 2A clinical trial in traumatic brain injury

The Defense Health Agency awarded Immunochem Therapeutics LLC $2,475,620 on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to advance an experimental antineuroinflammatory drug toward a Phase 2A clinical trial in traumatic brain injury.

Work is performed in Auburndale, Massachusetts, with a period of performance through July 31, 2029. The award funds development of an antineuroinflammatory therapeutic candidate intended to treat traumatic brain injury, building on Immunochem's prior federally funded research into MW189 and related neuroinflammatory treatments. The recipient has previously received over $7.5 million in federal research funding from the National Institute of Neurological Disorders and Stroke, National Institute on Aging, and National Cancer Institute since 2019 for preclinical studies, regulatory documentation, and clinical feasibility work on neuroinflammatory drug candidates.